Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Nibedita Bandyopadhyay"'
Autor:
Judy Wang, Patricia Martin-Romano, Philippe Cassier, Melissa Johnson, Eric Haura, Laurie Lenox, Yue Guo, Nibedita Bandyopadhyay, Michael Russell, Elizabeth Shearin, Josh Lauring, Laetitia Dahan
Publikováno v:
The oncologist. 27(7)
Background Patients with KRAS-mutant cancers have limited treatment options. Here we present a phase I study of JNJ-74699157, an oral, selective, covalent inhibitor of the KRAS G12C isoform, in patients with advanced cancer harboring the KRAS G12C mu
Autor:
Steven Sun, Mats Jerkeman, Simon Rule, Georg Hess, John Bothos, Isabelle Bence-Bruckler, Mathias Witzens-Harig, Nibedita Bandyopadhyay, Fritz Offner, Christopher Enny, Jessica Vermeulen, Dolores Caballero, Aleksandra Rizo, Shana Traina, Sriram Balasubramanian, Chiara Rusconi, Martin Dreyling, Cristina João, Seok-Goo Cho, Rodrigo Santucci Silva, Jenna D. Goldberg, Marek Trneny, Wojciech Jurczak
Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97f3968cb14298604d326493927a7acf
https://ruj.uj.edu.pl/xmlui/handle/item/117399
https://ruj.uj.edu.pl/xmlui/handle/item/117399
Publikováno v:
Pharmaceutical statistics. 6(2)
The study design was a multi-center, multiple-dose, randomized, open-label, 2 × 2 crossover study in patients with advanced solid tumors. Each patient was randomized to receive the test formulation or the reference formulation of the drug. The prima